Skip to main content

People in the News: Rob Metcalf, Joanne Spadoro, Todd Laird, and David Dimmock

Rob Metcalf

NextGxDx has appointed Rob Metcalf as CEO. Most recently, Metcalf served as president and chief operating officer for Digital Reasoning. He has also held multiple positions with LexisNexis, including as vice president of global operations for the company's practice management division. Metcalf succeeds Founder Mark Harris, who will step down as CEO and serve as the company's chief innovation officer.

Joanne Spadoro

T2 Biosystems has appointed Joanne Spadoro as chief operating officer. She has served as a member of the company's scientific advisory board, and as an operational consultant. Prior to joining T2, Spadoro was the chief scientific officer and vice president of worldwide operations at Immucor and senior vice president at Roche.

Todd Laird and David Dimmock

Rady Children's Hospital-San Diego has appointed Todd Laird as chief operating officer and David Dimmock as medical director. Most recently, Laird has been an active investor and advisor to a portfolio of early-stage life science companies. He has also held a variety of global operations and commercial roles with various companies, including American Hospital Supply, Baxter International, GE Healthcare, and Life Technologies. Before joining Rady Children's, Dimmock worked as a clinician and his practice focused on the diagnosis of heritable disorders in children and adults, and the longer term care of patients with mitochondrial and metabolic disorders. He has also been the principal investigator for multiple industry sponsored studies evaluating novel therapeutics for these disorders.

For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.